Phase 3 N=181 Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Serotype Opsonization Titers — 10.85; 12.63; 132.51; 908.23 titers
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=129 Reducing Length of Stay for Veterans Hospitalized With Pneumonia
Pneumonia
Primary: Length of Hospital Stay — 7.3; 5.8 Days
Phase 2 N=158 Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia
Pseudomonas Aeruginosa Pneumonia
Primary: Clinical Cure on Day 21 — 34; 37; 6; 5 Participants — p=0.6154
N/A N=1,027 Improving CarE for Community Acquired Pneumonia 1
Pneumonia Childhood
Primary: Exclusive Guideline-Concordant Antibiotic Therapy, First 24 Hours — 255; 284; 174; 120 Participants
N/A N=203 The Place of Imaging and Microbiology in the Diagnosis of Pneumonia in the Elderly
Pneumonia
Primary: Number of Patients With Modified Diagnosis Probability After Low Dose CT (LDCT) — 10; 3; 4; 34 Participants
N/A N=66 Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine
Community Acquired Pneumonia
Primary: Use of Antibiotics in Each Group — 9; 21 participants — p=0.01
N/A N=120 Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Community Acquired Pneumonia
Pneumonia
Primary: Use of Antibiotics in Each Group — 28; 52 participants
Phase 2 N=248 A Study of a Vaccine for Pneumonia in Adults and Toddlers in Kenya
Pneumonia
Primary: Highest Grade of Reactogenicity Events in the Adult Cohort: Vaccination 1 — 11; 12; 22; 1 Participants
N/A N=75 Urease Breath Test for Rapid Characterization of Pneumonia
Pneumonia, Bacterial
Primary: Adverse Events — 3; 0; 1; 0 Participants
Phase 3 N=725 Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
Pneumonia, Bacterial
Primary: Number of Participants Surviving Through LFU Visit — 191; 196; 64; 57 Participants — p=0.4263
Phase 3 N=23,738 COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine
Infections, Streptococcal
Primary: Number of Subjects With a First Episode Reported of Bacterial Community Acquired Pneumoniae (B-CAP) — 240; 304 Subjects
N/A N=188 Implementing a Combination of Clinical Parameters, Biomarkers and SoCs for the Etiology Diagnoses of Pneumonia in Pediatric Patients
Pneumonia
Primary: White Blood Cells and Absolute Neutrophil Count Cut-off Levels for Distinguishing of Viral and Bacterial/Mixed Pathogens — 12.2; 6.15 10^3 cells/microliter — p=0.0048
N/A N=154 Oropharyngeal Dysphagia in Patients With Community Acquired Pneumonia
Dysphagia · Pneumonia
Primary: Intra Hospital Mortality — 7; 0 Participants
Phase 2 N=183 An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia
Pneumonia · Bacterial Pneumonia · Ventilator-Associated Pneumonia
Primary: Clinical Response Rates and 95% Confidence Intervals at the Test-of-Cure Assessment. — 63.9; 66.0; 64.4; 50.0 Percentage of participants
Early Phase 1 N=5 Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia
Pneumonia · Pediatric Respiratory Diseases · Antibiotic Use
Primary: Total Pilot Trial Enrollment — 0; 1 Participants
Phase 3 N=764 A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
Community-Acquired Bacterial Pneumonia · Lung Infection of Individual Not Recently Hospitalized
Primary: Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at Test of Cure (TOC) in CE Population — 217; 178; 41; 62 Participants
Phase 2 N=158 Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia
Community-Acquired Pneumonia (CAP)
Primary: Clinical Cure in the Clinically Evaluable (CE) Population at Test of Cure (TOC) — 34; 37; 32 Participants
Phase 2 N=314 Strategies To Prevent Pneumonia 2 (SToPP2)
Infections, Hospital · Ventilator-Associated Pneumonia · Mechanical Ventilation Complication
Primary: Development of VAP (Clinical Pulmonary Infection Score) — 4.13; 4.45 units on a scale — p=0.1763
Phase 3 N=834 A Trial to Reduce Pneumonia in Nursing Home Residents
Pneumonia · Lower Respiratory Tract Infection
Primary: Pneumonia — 119; 94 participants
N/A N=74 Antibiotic Efficacy in Pneumonitis Following Paraffin (Kerosene) Ingestion in Children
Kerosene Pneumonitis
Primary: Treatment Failure — 3; 2 participants — p=>0.50
Phase 2 N=188 Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects
Pseudomonas Aeruginosa
Primary: Percentage of Participants With Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa — 18.1; 12.5; 22.4 Percentage of participants — p=0.491
Phase 2 N=39 Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Accelerated Phase Chronic Myelogenous Leukemia · Blastic Phase Chronic Myelogenous Leukemia · Childhood Acute Lymphoblastic Leukemia in Remission
Primary: Response of IPS (Idiopathic Pneumonia Syndrome) to Etanercept Plus Corticosteroid Therapy by Day 28. — 20; 8 participants
Phase 3 N=527 Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
Pneumonia
Primary: Treatment Failure at 48 Hours (Two Full Days After Enrollment) — 20; 21 participants
N/A N=536 Improving CarE for Community Acquired Pneumonia 1 (ICE-CAP2)
Pneumonia Childhood
Primary: Inappropriate Disposition — 7; 6 Participants
Phase 3 N=342 Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia
Pneumonia, Bacterial
Primary: Number of Patients With Clinical Success as Judged by the Investigator — 158; 145; 6; 8 Participants — p==0.499
N/A N=530 Clinical Characteristics and Microbiology of Healthcare Associated Pneumonia
Healthcare Associated Pneumonia
Primary: Pathogens of Healthcare Associated Pneumonia, Measured by the Number of Participants — 15; 51; 195; 269 Participants
Phase 3 N=670 Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
Community-acquired Pneumonia · Bacterial Pneumonia
Primary: Percentage of Participants With Early Clinical Response at the Early Clinical Response (ECR) Visit — 89.6; 87.7; 8.6; 9.3 Percentage of participants
Phase 3 N=859 Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
Community Acquired Bacterial Pneumonia
Primary: Early Clinical Response — 383; 381 Participants
Phase 2 N=35 A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization
Pneumonia, Bacterial
Primary: Percentage of Participants With Clinical Response at Test of Cure (TOC) Visit — 90.0; 87.5; 62.5; 10.0 percentage of participants
Phase 2 N=29 Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
Corona Virus Infection · SARS-CoV 2 · SARS Pneumonia
Primary: Number of Participants Transferred to Intensive Care Unit (ICU) — 4 Participants